Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PUBLICATIONS - New from Theta Reports - Proteomics 2002: Commercial & Technological Potentials

This article was originally published in Clinica

Executive Summary

1.1 Defining Proteomics What is proteomics? What is all the excitement about? Why all this sudden attention at conferences, in reports, in the media? Is it just a new buzzword? How does it relate to genomics? How will it impact drug discovery? Will it help people make money? If so, who and how? There are a lot of questions about proteomics, as well as a fair amount of confusion. This is to be expected with a new area of science that has burst upon the scene so quickly. This report is designed to help answer these questions and to provide readers with a roadmap through this complex and multifaceted area.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts